Somatic CHEK1 loss-of-function in EOC: rare (<1%); included in some HRR panel definitions...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-CHEK1-SOMATIC-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | CHEK1 somatic loss-of-function |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIIA |
| Recommended combinations | consider PARPi off-label (HRD-positive context), platinum-based chemo |
| Evidence summary | Somatic CHEK1 loss-of-function in EOC: rare (<1%); included in some HRR panel definitions but evidence for PARPi benefit weaker than core HRR genes. NCCN HRR panel inclusion is variable. ESCAT IIIA / OncoKB Level 3B. |
Notes
Some HRR panels exclude CHEK1; verify with composite HRD score.
Used By
No reverse references found in the YAML corpus.